Literature DB >> 16795039

Comparison of various kinds of bone marrow stem cells for the repair of infarcted myocardium: single clonally purified non-hematopoietic mesenchymal stem cells serve as a superior source.

Shaoheng Zhang1, Junbo Ge, Aijun Sun, Danling Xu, Juying Qian, Jinyi Lin, Yan Zhao, Haifeng Hu, Ying Li, Keqiang Wang, Yunzeng Zou.   

Abstract

A variety of adult stem cells have been used to transplant into the infarcted (MI) heart, however, comparative studies are lacking to show more suitable source of cells for transplantation. We have identified a single non-hematopoietic mesenchymal stem cell subpopulation (snMSCs) isolated from human bone marrow and clonally purified, that over 99% of them expressed MSC marker proteins and cardiomyocyte marker proteins when induction in vitro. We also compared the effects of the snMSCs with unpurified MSC (uMSCs), mononuclear cells (BMMNCs), or peripheral blood mononuclear cells (PBMNCs) on myocardial repair after induction of MI in rats. Ninety days later, we observed a better cardiac function assessed by ejection fraction, fraction of shortening and lung wet/dry weight ratios, less remodeling of left ventricle (LV), lower collagen density in the LV, and more vessels in the ischemic wall in the snMSCs transplantation group than in other cell-transplanted groups. Furthermore, the transplanted cells expressing cardiomyocyte specific proteins or vascular endothelial cell marker proteins were more in the snMSCs group than in other ones. We conclude that transplantation with single clonally purified MSCs seems to be more beneficial to the cardiac repair than with other stem cells after MI.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16795039     DOI: 10.1002/jcb.20949

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  31 in total

1.  Density-Dependent Metabolic Heterogeneity in Human Mesenchymal Stem Cells.

Authors:  Yijun Liu; Nathalie Muñoz; Bruce A Bunnell; Timothy M Logan; Teng Ma
Journal:  Stem Cells       Date:  2015-08-14       Impact factor: 6.277

2.  Unraveling the mechanistic basis of mesenchymal stem cell activity in the heart.

Authors:  Loren J Field
Journal:  Mol Ther       Date:  2006-10-27       Impact factor: 11.454

Review 3.  Molecular basis of functional myogenic specification of Bona Fide multipotent adult cardiac stem cells.

Authors:  Eleonora Cianflone; Iolanda Aquila; Mariangela Scalise; Pina Marotta; Michele Torella; Bernardo Nadal-Ginard; Daniele Torella
Journal:  Cell Cycle       Date:  2018-06-25       Impact factor: 4.534

Review 4.  Cell therapy of peripheral arterial disease: from experimental findings to clinical trials.

Authors:  Zankhana Raval; Douglas W Losordo
Journal:  Circ Res       Date:  2013-04-26       Impact factor: 17.367

5.  Comparative study of three types of polymer materials co-cultured with bone marrow mesenchymal stem cells for use as a myocardial patch in cardiomyocyte regeneration.

Authors:  Hongxing Niu; Junsheng Mu; Jianqun Zhang; Ping Hu; Ping Bo; Yan Wang
Journal:  J Mater Sci Mater Med       Date:  2013-04-26       Impact factor: 3.896

6.  Clonal analysis of the proliferation potential of human bone marrow mesenchymal stem cells as a function of potency.

Authors:  Katie C Russell; Michelle R Lacey; Jennifer K Gilliam; H Alan Tucker; Donald G Phinney; Kim C O'Connor
Journal:  Biotechnol Bioeng       Date:  2011-05-10       Impact factor: 4.530

7.  Cell-surface expression of neuron-glial antigen 2 (NG2) and melanoma cell adhesion molecule (CD146) in heterogeneous cultures of marrow-derived mesenchymal stem cells.

Authors:  Katie C Russell; H Alan Tucker; Bruce A Bunnell; Michael Andreeff; Wendy Schober; Andrew S Gaynor; Karen L Strickler; Shuwen Lin; Michelle R Lacey; Kim C O'Connor
Journal:  Tissue Eng Part A       Date:  2013-05-30       Impact factor: 3.845

8.  High density lipoprotein cholesterol promotes the proliferation of bone-derived mesenchymal stem cells via binding scavenger receptor-B type I and activation of PI3K/Akt, MAPK/ERK1/2 pathways.

Authors:  Jianfeng Xu; Juying Qian; Xinxing Xie; Li Lin; Jianying Ma; Zheyong Huang; Mingqiang Fu; Yunzeng Zou; Junbo Ge
Journal:  Mol Cell Biochem       Date:  2012-08-14       Impact factor: 3.396

9.  Bone marrow cell therapy ameliorates and reverses chagasic cardiomyopathy in a mouse model.

Authors:  Regina C S Goldenberg; Linda A Jelicks; Fabio S A Fortes; Louis M Weiss; Leonardo L Rocha; Dazhi Zhao; Antonio Campos de Carvalho; David C Spray; Herbert B Tanowitz
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

10.  Cell tracking and therapy evaluation of bone marrow monocytes and stromal cells using SPECT and CMR in a canine model of myocardial infarction.

Authors:  Gerald Wisenberg; Katie Lekx; Pam Zabel; Huafu Kong; Rupinder Mann; Peter R Zeman; Sudip Datta; Caroline N Culshaw; Peter Merrifield; Yves Bureau; Glenn Wells; Jane Sykes; Frank S Prato
Journal:  J Cardiovasc Magn Reson       Date:  2009-04-27       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.